Stay updated on Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial page.

Latest updates to the Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedAdded a Locations section listing California and Tennessee study sites; removed the separate California Locations and Tennessee Locations entries. Revision: v3.3.3.SummaryDifference0.3%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedNew study record dates were added (e.g., 2025-12-05, 2025-12-03) and the primary completion date is listed as 2026-07-01; contemporaneously, earlier date entries (2025-08-26, 2025-08-22, 2025-11-17) were removed.SummaryDifference0.3%

- Check41 days agoChange DetectedRevision notes were updated to add v3.3.2 and remove v3.2.0, with no visible changes to the study content or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedThe government funding/operating status notice at the top of the page has been removed. The study details, eligibility criteria, and related links remain unchanged.SummaryDifference0.4%

- Check62 days agoChange DetectedThe screenshots show minor administrative updates to the study page (such as the last update timestamp and formatting tweaks) with no changes to the core study details, eligibility criteria, outcomes, or contacts. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check91 days agoChange DetectedAdded a government funding operation-status notice and updated version to v3.2.0; removed the AA amyloidosis resource and the old v3.1.0 tag.SummaryDifference3%

Stay in the know with updates to Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab Post-Transplant in Multiple Myeloma Clinical Trial page.